title: Immunohistochemistry of affected tissue may guide cGVHD treatment decisions.
abstract: Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20+ and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.
authors.affiliation: Department of Pediatric Hematology-Oncology, Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. williaki@mail.nih.gov
authors.forename: K M
authors.initials: KM
authors.lastname: Williams
authors.forename: L W
authors.initials: LW
authors.lastname: Ostrow
authors.forename: D M
authors.initials: DM
authors.lastname: Loeb
authors.forename: T
authors.initials: T
authors.lastname: Chung
authors.forename: R D
authors.initials: RD
authors.lastname: Cohn
authors.forename: A M
authors.initials: AM
authors.lastname: Corse
authors.forename: A L
authors.initials: AL
authors.lastname: Mammen
authors.forename: A R
authors.initials: AR
authors.lastname: Chen
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002648:Child; D003882:Dermatomyositis / Q000473:pathology / Q000628:therapy; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007150:Immunohistochemistry; D017285:Polymyositis / Q000473:pathology / Q000628:therapy; D000069283:Rituximab; D000097382:CD68 Molecule
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D018951:Antigens, CD20; D015214:Antigens, Differentiation, Myelomonocytic; D000069283:Rituximab; C067980:CD68 antigen, human; D000097382:CD68 Molecule